CX-5461 was also found to be selectively lethal in BRCA1/2 deficient tumours possibly via stabilization of G-quadruplex structures and is currently in clinical phase I for BRCA1/2-deficient tumours (123). The gene discussed is BRCA1; the disease is neoplasm.